In NSCLC, this has established the EGFR tyrosine kinase (TK) as a critical target, prompting the development of various tyrosine kinase inhibitors (EGFR-TKIs) to suppress its abnormal activity [22]. This evidence concerns the gene TKT and non-small cell lung carcinoma.